Project Grant HT94252510872
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $414K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The University of Texas MD Anderson Cancer Center was awarded a $893,525.00 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "Targeting Neuronal Mimicry in SMARCB1-Deficient Renal Medullary Carcinoma Treatment." The award period runs from September 1, 2025 to August 31, 2028. As a leading academic cancer research institution, MD Anderson will leverage its expertise in areas such as immunotherapy,...
- The University of Texas MD Anderson Cancer Center was awarded a $758,337 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 2021 through September 2024 to target resistance mechanisms in tumors deficient in the SMARCB1 gene. The Military Medical Research and Development program supports biomedical research that transforms military and public health care through...
- The University of Texas MD Anderson Cancer Center received a $567,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 1, 2024, will fund research targeting myeloid mimicry in renal medullary carcinoma, with a completion date of August 31, 2027. Through this federal grant, MD Anderson Cancer Center will conduct innovative scientific studies, ranging from basic laboratory research to advanced...
- The Project Grant award titled "TARGETING PRMT3-IGF2BP1 AXIS-MEDIATED EPITRANSCRIPTOMIC REPROGRAMMING AS A NOVEL THERAPEUTIC STRATEGY TO OVERCOME IMMUNOTHERAPY RESISTANCE IN CCRCC" was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $1,144,500 award to the University of Texas MD Anderson Cancer Center will fund research from September 1, 2025 through August 31, 2028 focused on developing novel therapeutic strategies to...
- The University of Texas MD Anderson Cancer Center received a $456,662 Project Grant award from the Department of the Army Medical Command on September 30, 2021 to fund research targeting resistance mechanisms in SMARCB1-deficient tumors. The grant is part of the Military Medical Research and Development program administered by the Department of Defense under Assistance Listing Number 12.420. This program supports biomedical research that transforms military and public health care through...
- The Department of the Army Medical Command awarded a $249,999 Project Grant to The University of Texas M.D. Anderson Cancer Center through the Military Medical Research and Development program. This three-year grant will fund research from September 2022 to August 2025 to revisit antiangiogenic therapy and target prostate cancer metabolism. The Military Medical Research and Development program, designated by CFDA #12.420, supports basic, applied, and advanced biomedical research with the goals...
- This federal Project Grant award of $1,348,314.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The University of Texas MD Anderson Cancer Center. The funding supports a research project titled "BUILDING T-CELL PRODUCTS IN NF1-ASSOCIATED MPNST THROUGH ANTIGEN DISCOVERY AND EPIGENOME TARGETING". The project aims to conduct advanced biomedical research to transform healthcare for military service members,...
- This $1,619,723 federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides funding to The University of Texas MD Anderson Cancer Center to conduct research targeting novel mediators of breast cancer brain metastasis. The award period runs from April 1, 2024 to March 31, 2027, with the goal of developing new treatments, improving patient care, and advancing scientific understanding in this...
- This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $1,444,922.00 to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct research on a novel epigenetic determinant in metastatic prostate cancer. The award period is from September 15, 2024 to September 14, 2027. MD Anderson, a comprehensive cancer research and treatment center, will utilize this funding to carry out basic,...
- The federal Project Grant award of $735,799.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is awarded to the University of Texas MD Anderson Cancer Center to support the project "INNOVATING BREAST CANCER RNA THERAPY: MECHANISMS AND PHARMACOGENETIC INHIBITORS". The project aims to conduct advanced biomedical research focused on transforming healthcare for military service members and the broader public,...